de Jonge, P. K. J. D.
van Hauten, P. M. M.
Janssen, L. D.
de Goede, A. L.
Berrien-Elliott, M. M.
van der Meer, J. M. R.
Mousset, C. M.
Roeven, M. W. H.
Foster, M.
Blijlevens, N.
Hobo, W.
Fehniger, T. A.
Jansen, J. H.
Schaap, N. P. M.
Dolstra, H.
Funding for this research was provided by:
KWF Kankerbestrijding (10100)
National Institutes of Health (R01CA205239)
Article History
Received: 23 March 2023
Accepted: 30 June 2023
First Online: 21 July 2023
Declarations
:
: This work was supported by the Dutch Cancer Society KWF, grant numbers 10100 and 11564, and NIH grants R01CA205239, P50CA171963. Radboudumc is patent holder of the improved method for ex vivo expansion CD34<sup>+</sup> HSPCs into NK cells using an aryl hydrocarbon receptor antagonist (PCT/EP2016/071660). The authors have no other relevant financial or non-financial interests to disclose.
: Approval of the clinical trial was granted by the Competent Authority The Ministry of Health, Welfare and Sports in The Netherlands and by the Dutch Central Committee on Research Involving Human Subjects (CCMO, EudraCT 2019-001929-27). The study will be performed in line with the principles of the Declaration of Helsinki.